MedTrace Logo

Effect of Ranibizumab on Malignant Conjunctival Neoplasia

NCT00456495 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2017-07-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the safety and tolerability of subconjunctival injection of ranibizumab in the treatment of malignant conjunctival neoplasia using the incidence and severity of adverse events.

Our secondary objective is to assess the efficacy of ranibizumab treatment on malignant conjunctival neoplasia by evaluating tumor destruction or reduction as documented by slit-lamp photography and ultrasonographic imaging and the regression of blood vessels.

Conditions

  • Conjunctival Neoplasms

Interventions

DRUG

ranibizumab

Subconjunctival injection of drug every 2 to 4 weeks

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • The New York Eye Cancer Center

    lead OTHER

Principal Investigators

  • Paul T. Finger, MD · The New York Eye Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00456495 on ClinicalTrials.gov